Showing results (321-330 of 395) with videos related to
Sort By:
Pageof 40
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study GroupGiuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Identifying breast cancer patients at high risk for bone metastasesM Colleoni, A O'Neill, A Goldhirsch, et al.British Journal of Cancer|June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMFM Colleoni, H J Litman, M Castiglione-Gertsch, et al.Annals of Surgical Oncology|September 25, 2016
Poor Prognosis After Second Locoregional Recurrences in the CALOR TrialIrene L Wapnir, Shari Gelber, Stewart J Anderson, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VIID Crivellari, M Bonetti, M Castiglione-Gertsch, et al.Pageof 40